Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is apparently in advanced talks to acquire biopharmaceutical firm ImClone. The Wall Street Journal reports the deal could be worth $6.1 billion, or $70 a share. ImClone announced earlier this week an unnamed company, which has offered that share price, would either make a formal proposal, or withdraw by midnight Wednesday. ...